EyeFocus Eye Care Innovation Conference

31 January 2017, London, UK.
EyeFocus is holding a one day conference about eye-care innovation to end the second EyeFocus program. The conference is instead of the traditional demo day, and will go beyond startups pitching to investors, instead presenting the ecosystem EyeFocus has built in eye-care innovation.

The conference will bring together thought leaders from across eye-care, innovation, and tech. The day will feature keynote talks, discussion panels, and short pitches from a broad range of the companies in the EyeFocus program, from startups to developed businesses.

The aim of the day is to share the built ecosystem, and the knowledge clustered around EyeFocus, and to promote innovation in eye-care. The day will be a mix of networking, education, and information for people working in eye-care, health tech, and startups.

EyeFocus Eye Care Innovation Conference is sponsored by Bayer, and has partnered with the world famous Royal National Institute for Blind People (RNIB), and Royal Academy of Engineering (RAENG) to bring thought leaders from across the eye-care spectrum together for a unique event in the centre of London.

For further information and to buy tickets, please visit:
https://www.eventbrite.com/e/eyefocus-conference-tickets-29612858858?aff=eHealthNews&afu=197085922377

About EyeFocus
EyeFocus is the world's first eye-care accelerator and innovation program. We run events around the world to bring together opinion leaders and practitioners in eye-care innovation to leave our ecosystem better connected, and to focus academics, innovators, and practitioners on thinking about how to create new products and solutions for people who are blind or visually impaired.

EyeFocus is a project of Newsquare Innovation. Newsquare develops programs to create connected ecosystems in healthcare innovation, accelerating early stage companies, and building bridges between academia, industry, entrepreneurs, and healthcare.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]